Completed

GabapentiGabapentin for Treating Flushing/Erythema in Rosacea: Safety and Effectiveness

Study Aim

This study aims to evaluate the safety and effectiveness of Gabapentin in reducing flushing and erythema (redness) associated with Rosacea, by assessing the changes in the Clinician Erythema Assessment score over a period of 12 weeks.

What is being tested

minocycline combined with hydroxychloroquine

+ gabapentin 300mg bid

+ gabapentin 300mg tid

Drug

Who is being recruted

Rosacea

+ Skin Diseases

+ Skin and Connective Tissue Diseases

From 12 to 60 Years

+2 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Phase 1

Interventional

Study Start: January 2024

See protocol details

Summary

Principal SponsorFirst Affiliated Hospital of Chongqing Medical University

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: January 5, 2024

Actual date on which the first participant was enrolled.

This clinical trial is exploring if the medication Gabapentin can effectively treat redness and flushing in people who have rosacea, a skin condition causing facial redness. The study also aims to assess the safety of Gabapentin when used for this purpose. Rosacea can be difficult to manage, and finding effective treatments is important for those affected. Currently, treatments like minocycline and hydroxychloroquine are used as a standard approach, and this trial will see how Gabapentin compares to these existing options. Participants in this study will receive Gabapentin and its effects on reducing facial flushing and redness will be monitored. The trial will involve a comparison with other established treatments to see if Gabapentin is more effective. Researchers will closely watch for any medical issues that arise while taking Gabapentin to ensure its safety. The outcomes of this study could lead to improved treatment options for those suffering from rosacea.

Official TitleEfficacy and Safety of Different Dose Regimens of Gabapentin for Treating Erythema/Flushing in Rosacea: A Randomized Controlled Trial

NCT06776445

Principal SponsorFirst Affiliated Hospital of Chongqing Medical University

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

50 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 12 to 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

RosaceaSkin DiseasesSkin and Connective Tissue Diseases

Criteria

1 inclusion criteria required to participate

Initial treatment in our hospital; 2 Diagnosed by two experienced dermatologists and in accordance with the updated diagnostic criteria of the National Rosacea Society (NRS) Expert Committee [38], unconscious disorder and no communication disorder; 3 did not receive any other form of treatment within 4 weeks; 4 Patients who were followed up for 8 weeks or more and had complete clinical data; 5 Informed consent was signed before treatment, and the clinical data were agreed to be used for scientific research

1 exclusion criteria prevent from participating

received other treatment within 4 weeks of this treatment; 2 facial flushing caused by other diseases and local irritation; 3 Patients with contraindication to minocycline, hydroxychloroquine, gabapentin and carvedilol; 4 Unable to complete follow-up and serum specimen collection; ○5 patients were intolerant to minocycline, hydroxychloroquine and carvedilol; ○6 Lactation, pregnancy, liver and kidney dysfunction, psychiatric diseases, cardiovascular and cerebrovascular diseases, systemic lupus erythematosus and other systemic diseases

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

3 intervention groups are designated in this study

This study does not include a placebo group

Treatment Groups

Group I

Experimental

This group receives a combination of minocycline and hydroxychloroquine to treat rosacea. The effectiveness of this treatment is compared with other groups receiving different medications.

Group II

Active Comparator

In this group, participants receive Gabapentin 300mg two times a day. This is an active treatment, not a placebo or control group.

Group III

Active Comparator

Participants in this group receive Gabapentin 300mg three times a day. This is an active treatment, not a placebo.

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

First Affiliated Hospital of Chongqing Medical University

Chongqing, ChinaOpen First Affiliated Hospital of Chongqing Medical University in Google Maps

CompletedOne Study Center